Baijin Life Science Holdings (HKG:1466) is poised to raise HK$31.3 million in net proceeds from issuing 65.3 million shares to 20 subscribers.
The subscription price is HK$0.48 per share, according to a Tuesday filing with the Hong Kong bourse.
The funds raised will be utilized for the company's general working capital.
Completion is subject to regulatory approvals, and the company has applied for listing permission from the Hong Kong Exchange.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。